Several previous studies demonstrated that dabrafenib actually inhibits the RIPK3-mediated phosphorylation of MLKL in vitro using human melanoma cells, human dermal fibroblasts, human colon cancer cells, and leukemia cells [30,33,53]. This evidence concerns the gene MLKL and colonic neoplasm.